Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
Find more results for ICPT
219.07
-1.35 (-0.61%)
After Hours: 218.70 -0.37 (-0.17%)
Feb 26, 7:49PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 216.00 - 221.99
52 week 128.50 - 484.99
Open 221.11
Vol / Avg. 237,884.00/566,078.00
Mkt cap 4.94B
P/E     -
Div/yield     -
EPS -12.76
Shares 22.57M
Beta     -
Inst. own 70%
Mar 3, 2015
Intercept Pharmaceuticals Inc at Cowen Health Care Conference - 11:20AM EST - Add to calendar
Mar 2, 2015
Q4 2014 Intercept Pharmaceuticals Inc Earnings Release - 9:30AM EST - Add to calendar
Mar 2, 2015
Q4 2014 Intercept Pharmaceuticals Inc Earnings Call - 8:30AM EST - Add to calendar
Jan 14, 2015
Intercept Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 14, 2015
Intercept Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 2, 2014
Intercept Pharmaceuticals Inc at Deutsche Bank BioFEST
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -8047.25% -4180.51%
Operating margin -8098.50% -2432.84%
EBITD margin - -2426.33%
Return on average assets -48.18% -51.65%
Return on average equity -52.18% -91.41%
Employees 50 -
CDP Score - -

Address

SUITE 505, 450 W. 15TH STREET
NEW YORK, NY 10011
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company�s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA selectively binds to and induces activity in the farnesoid X receptor, or FXR, which has broad liver-protective properties. The Company is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. It is conducting a Phase III clinical trial of OCA in PBC. Its other products are INT-767 and INT-777.

Officers and directors

Jonathan T. Silverstein J.D. Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Barbara G. Duncan Chief Financial Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
David M. Shapiro M.D. Chief Medical Officer, Executive Vice President - Development
Age: 59
Bio & Compensation  - Reuters
Luciano Adorini M.D. Chief Scientific Officer
Bio & Compensation  - Reuters
Rachel L. McMinn Ph.D. Chief Strategy Officer
Age: 41
Bio & Compensation  - Reuters
Daniel P. Regan Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Paolo Fundaro Independent Director
Age: 40
Bio & Compensation  - Reuters
Sanj K. Patel Independent Director
Age: 44
Bio & Compensation  - Reuters